{
    "Trade/Device Name(s)": [
        "Emit\u00ae II Plus Buprenorphine Assay"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K221605",
    "Predicate Device Reference 510(k) Number(s)": [
        "K150606"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "March 16, 2023",
    "Summary Letter Received Date": "March 17, 2023",
    "Submission Date": "July 7, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Buprenorphine"
    ],
    "Specimen Type(s)": [
        "Human urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Beckman Coulter DxC 500 AU Clinical Chemistry Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay",
        "Absorbance measured spectrophotometrically"
    ],
    "Methodologies": [
        "Enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Emit\u00ae II Plus Buprenorphine Assay, an enzyme immunoassay for buprenorphine detection in human urine on the Beckman Coulter DxC 500 AU analyzer",
    "Indications for Use Summary": "Qualitative and/or semiquantitative analysis of buprenorphine in human urine in clinical laboratories using a 5 ng/mL cutoff; provides preliminary test results and requires confirmation by alternative chemical methods such as LC/MS or GC/MS",
    "fda_folder": "Toxicology"
}